{"transactions":[{"id":908383,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66778,"kind":"person","name":"Palczuk Linda","position":1,"cik":"0001717580","reported_name":"Palczuk Linda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-12T17:35:08.000Z","date":"2026-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":11000,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Options are held by a revocable trust of which the Reporting Person is trustee."}],"balance_after":0,"derivative":{"exercise_price":10.83,"expiration_date":"2035-07-29","underlying":"Ordinary Shares","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001104659-26-014446","document":"tm266121-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000110465926014446/tm266121-7_4seq1.xml","form_type":"4"}},{"id":908382,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66778,"kind":"person","name":"Palczuk Linda","position":1,"cik":"0001717580","reported_name":"Palczuk Linda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-12T17:35:08.000Z","date":"2026-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":25000,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Options are held by a revocable trust of which the Reporting Person is trustee."}],"balance_after":0,"derivative":{"exercise_price":10.93,"expiration_date":"2034-12-17","underlying":"Ordinary Shares","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001104659-26-014446","document":"tm266121-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000110465926014446/tm266121-7_4seq1.xml","form_type":"4"}},{"id":908381,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66778,"kind":"person","name":"Palczuk Linda","position":1,"cik":"0001717580","reported_name":"Palczuk Linda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-12T17:35:08.000Z","date":"2026-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":11000,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Options are held by a revocable trust of which the Reporting Person is trustee."}],"balance_after":0,"derivative":{"exercise_price":16.32,"expiration_date":"2034-07-30","underlying":"Ordinary Shares","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001104659-26-014446","document":"tm266121-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000110465926014446/tm266121-7_4seq1.xml","form_type":"4"}},{"id":908380,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66778,"kind":"person","name":"Palczuk Linda","position":1,"cik":"0001717580","reported_name":"Palczuk Linda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-12T17:35:08.000Z","date":"2026-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":33000,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Options are held by a revocable trust of which the Reporting Person is trustee."}],"balance_after":0,"derivative":{"exercise_price":14.1,"expiration_date":"2033-08-01","underlying":"Ordinary Shares","underlying_shares":33000},"source":{"system":"sec-edgar","filing":"0001104659-26-014446","document":"tm266121-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000110465926014446/tm266121-7_4seq1.xml","form_type":"4"}},{"id":908379,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66778,"kind":"person","name":"Palczuk Linda","position":1,"cik":"0001717580","reported_name":"Palczuk Linda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-12T17:35:08.000Z","date":"2026-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":42000,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Options are held by a revocable trust of which the Reporting Person is trustee."}],"balance_after":0,"derivative":{"exercise_price":4.79,"expiration_date":"2032-08-03","underlying":"Ordinary Shares","underlying_shares":42000},"source":{"system":"sec-edgar","filing":"0001104659-26-014446","document":"tm266121-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000110465926014446/tm266121-7_4seq1.xml","form_type":"4"}},{"id":908378,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66778,"kind":"person","name":"Palczuk Linda","position":1,"cik":"0001717580","reported_name":"Palczuk Linda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-12T17:35:08.000Z","date":"2026-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":42000,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Options are held by a revocable trust of which the Reporting Person is trustee."}],"balance_after":0,"derivative":{"exercise_price":8.07,"expiration_date":"2031-08-03","underlying":"Ordinary Shares","underlying_shares":42000},"source":{"system":"sec-edgar","filing":"0001104659-26-014446","document":"tm266121-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000110465926014446/tm266121-7_4seq1.xml","form_type":"4"}},{"id":908377,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66778,"kind":"person","name":"Palczuk Linda","position":1,"cik":"0001717580","reported_name":"Palczuk Linda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-12T17:35:08.000Z","date":"2026-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":42000,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Options are held by a revocable trust of which the Reporting Person is trustee."}],"balance_after":0,"derivative":{"exercise_price":8.48,"expiration_date":"2030-08-07","underlying":"Ordinary Shares","underlying_shares":42000},"source":{"system":"sec-edgar","filing":"0001104659-26-014446","document":"tm266121-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000110465926014446/tm266121-7_4seq1.xml","form_type":"4"}},{"id":908376,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66778,"kind":"person","name":"Palczuk Linda","position":1,"cik":"0001717580","reported_name":"Palczuk Linda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-12T17:35:08.000Z","date":"2026-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":60000,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Options are held by a revocable trust of which the Reporting Person is trustee."}],"balance_after":0,"derivative":{"exercise_price":2.03,"expiration_date":"2029-08-07","underlying":"Ordinary Shares","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001104659-26-014446","document":"tm266121-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000110465926014446/tm266121-7_4seq1.xml","form_type":"4"}},{"id":908375,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66778,"kind":"person","name":"Palczuk Linda","position":1,"cik":"0001717580","reported_name":"Palczuk Linda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-02-12T17:35:08.000Z","date":"2026-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":78905,"price":21,"value":1657005.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of ordinary shares of Avadel Pharmaceuticals plc (\"Issuer\"), nominal value $0.01 per share (\"Ordinary Shares\"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by Amendment No. 1 to the Transaction Agreement dated November 18, 2025, (together the \"Transaction Agreement\") by and between Issuer and Alkermes plc (\"Parent\"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the \"Scheme\") pursuant to which Parent acquired Issuer."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the \"Effective Time\"), each outstanding Ordinary Share was converted into $21.00 in cash (the \"Cash Consideration\") and a non-transferable contingent value right entitling the holders to a potential additional cash payment of $1.50 per share, contingent upon achievement of certain milestones (each a \"CVR\")."},{"field":"shares","element":"transactionShares","label":"F3","text":"Includes Ordinary Shares previously subject to vesting restrictions or forfeiture back to Issuer (each, a \"Restricted Stock Award\"). Pursuant to the Transaction Agreement, at the Effective Time, each Restricted Stock Award that was outstanding immediately prior to the Effective Time vested in full and was treated in the manner described in footnote 1."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the disposition of ordinary shares of Avadel Pharmaceuticals plc (\"Issuer\"), nominal value $0.01 per share (\"Ordinary Shares\"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by Amendment No. 1 to the Transaction Agreement dated November 18, 2025, (together the \"Transaction Agreement\") by and between Issuer and Alkermes plc (\"Parent\"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the \"Scheme\") pursuant to which Parent acquired Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the \"Effective Time\"), each outstanding Ordinary Share was converted into $21.00 in cash (the \"Cash Consideration\") and a non-transferable contingent value right entitling the holders to a potential additional cash payment of $1.50 per share, contingent upon achievement of certain milestones (each a \"CVR\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-26-014446","document":"tm266121-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000110465926014446/tm266121-7_4seq1.xml","form_type":"4"}},{"id":1040914,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66778,"kind":"person","name":"Palczuk Linda","position":1,"cik":"0001717580","reported_name":"Palczuk Linda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-15T19:54:41.000Z","date":"2025-09-15","kind":"gift","planned":false,"acquired":false,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest in full on the earlier to occur of (a) July 29, 2026 or (b) the date of the next annual general meeting of shareholders following the date of grant, subject to the Reporting Person's continued service at such time."}],"balance_after":0,"derivative":{"exercise_price":10.83,"expiration_date":"2035-07-29","underlying":"Ordinary Shares","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001104659-25-090116","document":"tm2526163-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000110465925090116/tm2526163-2_4seq1.xml","form_type":"4"}},{"id":1078629,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66778,"kind":"person","name":"Palczuk Linda","position":1,"cik":"0001717580","reported_name":"Palczuk Linda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-31T16:09:56.000Z","date":"2025-07-29","kind":"grant","planned":false,"acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options shall vest in full on the earlier to occur of (a) July 29, 2026 or (b) the date of the next annual general meeting of shareholders following the date of grant, subject to the Reporting Person's continued service at such time."}],"balance_after":11000,"derivative":{"exercise_price":10.83,"expiration_date":"2035-07-29","underlying":"Ordinary Shares","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001104659-25-072692","document":"tm2522138-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000110465925072692/tm2522138-5_4seq1.xml","form_type":"4"}},{"id":1078628,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66778,"kind":"person","name":"Palczuk Linda","position":1,"cik":"0001717580","reported_name":"Palczuk Linda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2025-07-31T16:09:56.000Z","date":"2025-07-29","kind":"grant","planned":false,"acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted share award. The shares shall vest in full on the earlier to occur of (a) July 29, 2026 or (b) the date of the next annual general meeting of shareholders following the date of grant, subject to the Reporting Person's continued service at such time."}],"balance_after":78900,"source":{"system":"sec-edgar","filing":"0001104659-25-072692","document":"tm2522138-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000110465925072692/tm2522138-5_4seq1.xml","form_type":"4"}},{"id":1293399,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66778,"kind":"person","name":"Palczuk Linda","position":1,"cik":"0001717580","reported_name":"Palczuk Linda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-28T16:22:54.000Z","date":"2025-01-24","kind":"gift","planned":false,"acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options become exercisable in three equal annual installments on each of the first three anniversaries following the 12/17/2024 grant date, subject to the Reporting Person's continued service at each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":10.93,"expiration_date":"2034-12-17","underlying":"Ordinary Shares","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001104659-25-006709","document":"tm254584-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000110465925006709/tm254584-1_4seq1.xml","form_type":"4"}},{"id":1298194,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66778,"kind":"person","name":"Palczuk Linda","position":1,"cik":"0001717580","reported_name":"Palczuk Linda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2025-01-22T16:13:34.000Z","date":"2025-01-21","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":7.928,"value":39640.0,"ownership":{"direct":true},"balance_after":67900,"source":{"system":"sec-edgar","filing":"0001104659-25-005248","document":"tm254051-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000110465925005248/tm254051-1_4seq1.xml","form_type":"4"}},{"id":1321116,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66778,"kind":"person","name":"Palczuk Linda","position":1,"cik":"0001717580","reported_name":"Palczuk Linda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2024-12-27T16:15:11.000Z","date":"2024-12-24","kind":"gift","planned":false,"acquired":false,"shares":3500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":62900,"source":{"system":"sec-edgar","filing":"0001104659-24-132145","document":"tm2432060-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000110465924132145/tm2432060-1_4seq1.xml","form_type":"4"}},{"id":1325763,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66778,"kind":"person","name":"Palczuk Linda","position":1,"cik":"0001717580","reported_name":"Palczuk Linda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-19T16:20:43.000Z","date":"2024-12-17","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options become exercisable in three equal annual installments on each of the first three anniversaries following the 12/17/2024 grant date, subject to the Reporting Person's continued service at each such vesting date."}],"balance_after":25000,"derivative":{"exercise_price":10.93,"expiration_date":"2034-12-17","underlying":"Ordinary Shares","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001104659-24-130173","document":"tm2431478-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000110465924130173/tm2431478-1_4seq1.xml","form_type":"4"}},{"id":1337914,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66778,"kind":"person","name":"Palczuk Linda","position":1,"cik":"0001717580","reported_name":"Palczuk Linda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2024-12-10T07:00:19.000Z","date":"2024-12-06","kind":"purchase","planned":false,"acquired":true,"shares":3000,"price":10.1892,"value":30567.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.18 to $10.1899, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":66400,"source":{"system":"sec-edgar","filing":"0001104659-24-126999","document":"tm2430449-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000110465924126999/tm2430449-1_4seq1.xml","form_type":"4"}},{"id":1407077,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66778,"kind":"person","name":"Palczuk Linda","position":1,"cik":"0001717580","reported_name":"Palczuk Linda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-16T17:18:38.000Z","date":"2024-09-15","kind":"gift","planned":false,"acquired":false,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest in full on the earlier to occur of (a) July 30, 2025 or (b) the date of the next annual general meeting of shareholders following the date of grant (July 30, 2024), subject to the Reporting Person's continued service at such time."}],"balance_after":0,"derivative":{"exercise_price":16.32,"expiration_date":"2034-07-30","underlying":"Ordinary Shares","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001104659-24-100286","document":"tm2424180-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000110465924100286/tm2424180-1_4seq1.xml","form_type":"4"}},{"id":1444634,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66778,"kind":"person","name":"Palczuk Linda","position":1,"cik":"0001717580","reported_name":"Palczuk Linda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-01T16:38:32.000Z","date":"2024-07-30","kind":"grant","planned":false,"acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options shall vest in full on the earlier to occur of (a) July 30, 2025 or (b) the date of the next annual general meeting of shareholders following the date of grant, subject to the Reporting Person's continued service at such time."}],"balance_after":11000,"derivative":{"exercise_price":16.32,"expiration_date":"2034-07-30","underlying":"Ordinary Shares","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001104659-24-084944","document":"tm2420652-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000110465924084944/tm2420652-6_4seq1.xml","form_type":"4"}},{"id":1444633,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66778,"kind":"person","name":"Palczuk Linda","position":1,"cik":"0001717580","reported_name":"Palczuk Linda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2024-08-01T16:38:32.000Z","date":"2024-07-30","kind":"grant","planned":false,"acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted share units (\"RSUs\"). Each RSU represents the contingent right to receive one Ordinary Share upon vesting and settlement. The RSUs shall vest in full on the earlier to occur of (a) July 30, 2025 or (b) the date of the next annual general meeting of shareholders following the date of grant, subject to the Reporting Person's continued service at such time."}],"balance_after":63400,"source":{"system":"sec-edgar","filing":"0001104659-24-084944","document":"tm2420652-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000110465924084944/tm2420652-6_4seq1.xml","form_type":"4"}},{"id":1791286,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66778,"kind":"person","name":"Palczuk Linda","position":1,"cik":"0001717580","reported_name":"Palczuk Linda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-09-01T21:30:44.000Z","date":"2023-09-01","kind":"gift","planned":false,"acquired":false,"shares":33000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options shall vest in full on the earlier to occur of (a) August 1, 2024 or (b) the date of the next annual general meeting of shareholders following the date of grant (August 1, 2023), subject to the Reporting Person's continued service on the Board of Directors at such time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."}],"balance_after":0,"derivative":{"exercise_price":14.1,"expiration_date":"2033-08-01","underlying":"ADSs","underlying_shares":33000},"source":{"system":"sec-edgar","filing":"0001104659-23-097892","document":"tm2325379-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000110465923097892/tm2325379-2_4seq1.xml","form_type":"4"}},{"id":1816960,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66778,"kind":"person","name":"Palczuk Linda","position":1,"cik":"0001717580","reported_name":"Palczuk Linda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-03T16:16:47.000Z","date":"2023-08-01","kind":"grant","planned":false,"acquired":true,"shares":33000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options shall vest in full on the earlier to occur of (a) August 1, 2024 or (b) the date of the next annual general meeting of shareholders following the date of grant, subject to the Reporting Person's continued service on the Board of Directors at such time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."}],"balance_after":33000,"derivative":{"exercise_price":14.1,"expiration_date":"2033-08-01","underlying":"ADSs","underlying_shares":33000},"source":{"system":"sec-edgar","filing":"0001104659-23-087286","document":"tm2322778-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000110465923087286/tm2322778-2_4seq1.xml","form_type":"4"}},{"id":1898562,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66778,"kind":"person","name":"Palczuk Linda","position":1,"cik":"0001717580","reported_name":"Palczuk Linda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"ADSs","published_at":"2023-05-10T16:12:21.000Z","date":"2023-05-09","kind":"purchase","planned":false,"acquired":true,"shares":2500,"price":14.76,"value":36900.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."}],"balance_after":52400,"source":{"system":"sec-edgar","filing":"0001104659-23-058439","document":"tm2315307-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000110465923058439/tm2315307-1_4seq1.xml","form_type":"4"}},{"id":2047843,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66778,"kind":"person","name":"Palczuk Linda","position":1,"cik":"0001717580","reported_name":"Palczuk Linda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-24T17:00:51.000Z","date":"2023-01-20","kind":"gift","acquired":false,"shares":42000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"These options shall vest in full on the earlier to occur of (a) August 3, 2023 or (b) the date of the next annual general meeting of shareholders following the date of grant, subject to the Reporting Person's continued service on the Board of Directors at such time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."}],"balance_after":0,"derivative":{"exercise_price":4.79,"expiration_date":"2032-08-03","underlying":"ADSs","underlying_shares":42000},"source":{"system":"sec-edgar","filing":"0001104659-23-006235","document":"tm234325-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000110465923006235/tm234325-1_4seq1.xml","form_type":"4"}},{"id":2047842,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66778,"kind":"person","name":"Palczuk Linda","position":1,"cik":"0001717580","reported_name":"Palczuk Linda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-24T17:00:51.000Z","date":"2023-01-20","kind":"gift","acquired":false,"shares":42000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options are fully vested and exercisable as of the date hereof."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."}],"balance_after":0,"derivative":{"exercise_price":8.07,"expiration_date":"2031-08-03","underlying":"ADSs","underlying_shares":42000},"source":{"system":"sec-edgar","filing":"0001104659-23-006235","document":"tm234325-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000110465923006235/tm234325-1_4seq1.xml","form_type":"4"}},{"id":2047841,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66778,"kind":"person","name":"Palczuk Linda","position":1,"cik":"0001717580","reported_name":"Palczuk Linda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-24T17:00:51.000Z","date":"2023-01-20","kind":"gift","acquired":false,"shares":42000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These options become exercisable as to 14,000 ADSs on each of the first three anniversaries after the 08/07/2020 grant date, subject to the Reporting Person's continued service at each such vesting date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."}],"balance_after":0,"derivative":{"exercise_price":8.48,"expiration_date":"2030-08-07","underlying":"ADSs","underlying_shares":42000},"source":{"system":"sec-edgar","filing":"0001104659-23-006235","document":"tm234325-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000110465923006235/tm234325-1_4seq1.xml","form_type":"4"}},{"id":2047840,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66778,"kind":"person","name":"Palczuk Linda","position":1,"cik":"0001717580","reported_name":"Palczuk Linda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-24T17:00:51.000Z","date":"2023-01-20","kind":"gift","acquired":false,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options are fully vested and exercisable as of the date hereof."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."}],"balance_after":0,"derivative":{"exercise_price":2.03,"expiration_date":"2029-08-07","underlying":"ADSs","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001104659-23-006235","document":"tm234325-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000110465923006235/tm234325-1_4seq1.xml","form_type":"4"}},{"id":2075733,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66778,"kind":"person","name":"Palczuk Linda","position":1,"cik":"0001717580","reported_name":"Palczuk Linda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"ADSs","published_at":"2022-12-28T16:02:29.000Z","date":"2022-12-23","kind":"purchase","acquired":true,"shares":2000,"price":7.2025,"value":14405.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."}],"balance_after":49900,"source":{"system":"sec-edgar","filing":"0001104659-22-130515","document":"tm2233557-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000110465922130515/tm2233557-1_4seq1.xml","form_type":"4"}},{"id":2193757,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66778,"kind":"person","name":"Palczuk Linda","position":1,"cik":"0001717580","reported_name":"Palczuk Linda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-05T17:12:44.000Z","date":"2022-08-03","kind":"grant","acquired":true,"shares":42000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options shall vest in full on the earlier to occur of (a) August 3, 2023 or (b) the date of the next annual general meeting of shareholders following the date of grant, subject to the Reporting Person's continued service on the Board of Directors at such time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."}],"balance_after":42000,"derivative":{"exercise_price":4.79,"expiration_date":"2032-08-03","underlying":"ADSs","underlying_shares":42000},"source":{"system":"sec-edgar","filing":"0001104659-22-086771","document":"tm2222707-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000110465922086771/tm2222707-2_4seq1.xml","form_type":"4"}},{"id":2251985,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66778,"kind":"person","name":"Palczuk Linda","position":1,"cik":"0001717580","reported_name":"Palczuk Linda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"ADSs","published_at":"2022-05-31T07:17:03.000Z","date":"2022-05-27","kind":"purchase","acquired":true,"shares":10000,"price":1.6,"value":16000.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."}],"balance_after":47900,"source":{"system":"sec-edgar","filing":"0001104659-22-066227","document":"tm2217241-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000110465922066227/tm2217241-4_4seq1.xml","form_type":"4"}},{"id":2613592,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66778,"kind":"person","name":"Palczuk Linda","position":1,"cik":"0001717580","reported_name":"Palczuk Linda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-08-05T19:26:22.000Z","date":"2021-08-03","kind":"grant","acquired":true,"shares":42000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options shall vest in full on the earlier to occur of (a) August 3, 2022 or (b) the date of the next annual general meeting of shareholders following the date of grant, subject to the Reporting Person's continued service on the Board of Directors at such time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."}],"balance_after":42000,"derivative":{"exercise_price":8.07,"expiration_date":"2031-08-03","underlying":"ADSs","underlying_shares":42000},"source":{"system":"sec-edgar","filing":"0001179110-21-007964","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000117911021007964/edgar.xml","form_type":"4"}},{"id":3056355,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66778,"kind":"person","name":"Palczuk Linda","position":1,"cik":"0001717580","reported_name":"Palczuk Linda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"ADS","published_at":"2020-08-17T18:58:10.000Z","date":"2020-08-14","kind":"purchase","acquired":true,"shares":2500,"price":7.9399,"value":19849.75,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 27,900 restricted ADSs granted under the issuer's Omnibus Incentive Compensation Plan on 08/01/2018; one-third (1/3) of the ADSs will vest on each of the first three anniversaries of the grant date."}],"balance_after":37900,"source":{"system":"sec-edgar","filing":"0001179110-20-009084","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000117911020009084/edgar.xml","form_type":"4"}},{"id":3062383,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66778,"kind":"person","name":"Palczuk Linda","position":1,"cik":"0001717580","reported_name":"Palczuk Linda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-08-11T16:56:42.000Z","date":"2020-08-07","kind":"grant","acquired":true,"shares":42000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options become exercisable as to 14,000 ADSs on each of the first three anniversaries after the 08/07/2020 grant date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."}],"balance_after":42000,"derivative":{"exercise_price":8.48,"expiration_date":"2030-08-07","underlying":"ADSs","underlying_shares":42000},"source":{"system":"sec-edgar","filing":"0001179110-20-008889","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000117911020008889/edgar.xml","form_type":"4"}},{"id":3351328,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66778,"kind":"person","name":"Palczuk Linda","position":1,"cik":"0001717580","reported_name":"Palczuk Linda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"ADSs","published_at":"2019-12-05T16:29:00.000Z","date":"2019-12-03","kind":"purchase","acquired":true,"shares":7500,"price":5.91,"value":44325.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 27,900 restricted ADSs granted under the issuer's Omnibus Incentive Compensation Plan on 08/01/2018; one-third (1/3) of the ADSs will vest on each of the first three anniversaries of the grant date."}],"balance_after":35400,"source":{"system":"sec-edgar","filing":"0001104659-19-070213","document":"tm19244822_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000110465919070213/tm19244822_form4.xml","form_type":"4"}},{"id":3442657,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66778,"kind":"person","name":"Palczuk Linda","position":1,"cik":"0001717580","reported_name":"Palczuk Linda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-08-09T17:00:57.000Z","date":"2019-08-07","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Options become exercisable as to 20,000 ADSs on each of the first three anniversaries after the 08/07/2019 grant date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."}],"balance_after":60000,"derivative":{"exercise_price":2.03,"expiration_date":"2029-08-07","underlying":"ADSs","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001567619-19-016166","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000156761919016166/doc1.xml","form_type":"4"}},{"id":3619426,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":66778,"kind":"person","name":"Palczuk Linda","position":1,"cik":"0001717580","reported_name":"Palczuk Linda","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-03-04T17:31:05.000Z","date":"2019-02-28","kind":"grant","acquired":true,"shares":68260,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of shares subject to the option shall vest on February 28, 2020 (the \"Initial Vesting Date\"), and 1/48th of the shares subject to the Option shall vest each month thereafter on the same day of the month as the Initial Vesting Date, subject to the Reporting Person continuing to be a service provider through each such date."}],"balance_after":68260,"derivative":{"exercise_price":11.32,"expiration_date":"2029-02-27","underlying":"Common Stock","underlying_shares":68260},"source":{"system":"sec-edgar","filing":"0001209191-19-015814","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1717580/000120919119015814/doc4.xml","form_type":"4"}},{"id":3693221,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":66778,"kind":"person","name":"Palczuk Linda","position":1,"cik":"0001717580","reported_name":"Palczuk Linda","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2019-01-17T16:48:32.000Z","date":"2019-01-16","kind":"purchase","acquired":true,"shares":3000,"price":10.53,"value":31590.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $10.40 to $10.659, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Consists of 3,000 shares of common stock held by Ms. Palczuk and 5,500 shares of common stock held by Ms. Palczuk jointly with her spouse."}],"balance_after":8500,"source":{"system":"sec-edgar","filing":"0001209191-19-004240","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1717580/000120919119004240/doc4.xml","form_type":"4"}},{"id":3812979,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":66778,"kind":"person","name":"Palczuk Linda","position":1,"cik":"0001717580","reported_name":"Palczuk Linda","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2018-09-18T16:27:48.000Z","date":"2018-09-17","kind":"purchase","acquired":true,"shares":2500,"price":16.52,"value":41300.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $16.52 to $16.55, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Consists of 3,000 shares of common stock held by Ms. Palczuk and 2,500 shares of common stock held by Ms. Palczuk jointly with her spouse."}],"balance_after":5500,"source":{"system":"sec-edgar","filing":"0001209191-18-051471","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1717580/000120919118051471/doc4.xml","form_type":"4"}},{"id":3843474,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":66778,"kind":"person","name":"Palczuk Linda","position":1,"cik":"0001717580","reported_name":"Palczuk Linda","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2018-08-15T16:48:56.000Z","date":"2018-06-19","kind":"purchase","acquired":true,"shares":3000,"price":15,"value":45000.0,"ownership":{"direct":true},"balance_after":3000,"source":{"system":"sec-edgar","filing":"0001209191-18-046827","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1717580/000120919118046827/doc4.xml","form_type":"4"}},{"id":3855502,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66778,"kind":"person","name":"Palczuk Linda","position":1,"cik":"0001717580","reported_name":"Palczuk Linda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"ADSs","published_at":"2018-08-02T16:17:11.000Z","date":"2018-08-01","kind":"grant","acquired":true,"shares":27900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents 27,900 restricted ADSs granted under the issuer's Omnibus Incentive Compensation Plan on 08/01/2018; one-third (1/3) of the ADSs will vest on each of the first three anniversaries of the grant date."}],"balance_after":27900,"source":{"system":"sec-edgar","filing":"0001140361-18-035136","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114036118035136/doc1.xml","form_type":"4"}},{"id":4204115,"issuer":{"id":158290,"kind":"organization","name":"OSIRIS THERAPEUTICS, INC.","symbol":"OSIR"},"owners":[{"id":66778,"kind":"person","name":"Palczuk Linda","position":1,"cik":"0001717580","reported_name":"Palczuk Linda","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Incentive Stock Option (right to buy)","published_at":"2017-09-21T15:54:05.000Z","date":"2017-07-10","kind":"grant","acquired":true,"shares":25000,"price":6.67,"value":166750.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"6,250 shares underlying this option shall vest on each of July 10, 2018, July 10, 2019, July 10, 2020, and July 10, 2021, subject to Reporting Person's continued service through the applicable vesting date."}],"balance_after":25000,"derivative":{"exercise_price":6.67,"exercise_date":"2018-07-10","expiration_date":"2027-07-10","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001123292-17-001439","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1717580/000112329217001439/edgar.xml","form_type":"4"}}]}